Triptorelin

What is Triptorelin?

Triptorelin is a synthetic decapeptide GnRH superagonist (pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2) that is 13- to 21-fold more potent than native GnRH. A D-tryptophan substitution at position 6 confers enhanced receptor affinity and resistance to enzymatic degradation. Like other GnRH agonists, continuous administration causes an initial gonadotropin flare followed by profound pituitary desensitization, leading to medical castration levels of sex hormones. Triptorelin was first FDA-approved in 2000 (Trelstar) for advanced prostate cancer, and in 2017 (Triptodur) for central precocious puberty. It is also widely used internationally for endometriosis and as part of IVF protocols.

What Triptorelin Is Investigated For

Triptorelin is investigated and FDA-approved for advanced prostate cancer (Trelstar) and central precocious puberty (Triptodur), and is widely used internationally for endometriosis, uterine fibroids, IVF protocols, and ovarian suppression in premenopausal breast cancer. The strongest evidence is across the full GnRH agonist class indications, with triptorelin specifically supported by PRIORITI, GETUG 14, TALISMAN, and multiple Phase 3/4 endometriosis and precocious puberty trials. Its efficacy is essentially equivalent to leuprolide and goserelin — selection is driven by formulation availability and depot interval rather than meaningful efficacy differences. The honest caveats are class-level rather than triptorelin-specific: the initial testosterone or estrogen flare during the first 1–2 weeks requires anti-androgen pre-loading in high-tumor-burden prostate cancer, extended ADT causes bone mineral density loss and carries increased cardiovascular and metabolic risk, and recovery of gonadal function after discontinuation is gradual and incomplete in some older men. The bodybuilding-forum claim that a single 100 mcg dose 'resets' the HPG axis after anabolic steroid use has no controlled trial support, carries real risk of producing prolonged castrate-level suppression rather than brief reset, and is explicitly prohibited under WADA's S4 category.

History & Discovery

Triptorelin emerged from the European GnRH analog development effort in the late 1970s and early 1980s, parallel to (and sometimes pre-dating) the leuprolide work in the United States. The molecule — a decapeptide with D-tryptophan at position 6 — was developed by the Tulane group of Andrew Schally (whose foundational native LHRH work earned the 1977 Nobel Prize) and subsequently by European pharmaceutical partners including Beaufour-Ipsen. The D-Trp6 substitution conferred substantially enhanced receptor binding affinity and metabolic stability over native GnRH, making it among the most potent GnRH superagonists in the class. Decapeptyl (triptorelin) was launched in Europe in the late 1980s through Ipsen and Ferring partnerships for prostate cancer and endometriosis. In the United States, triptorelin pamoate (Trelstar) was developed by Watson Pharmaceuticals (later Allergan, then Debiopharm and Verity Pharmaceuticals partnerships) and received FDA approval in June 2000 for advanced prostate cancer — entering a market dominated by leuprolide. Triptodur (22.5 mg 6-month depot) was FDA-approved in June 2017 for central precocious puberty in pediatric patients age 2 and older, providing a longer-interval alternative to monthly leuprolide depot. Globally, triptorelin has broader approval than in the US — particularly for endometriosis (Decapeptyl is widely used across Europe, Asia, and Latin America), uterine fibroids, breast cancer in premenopausal women (where ovarian suppression complements adjuvant endocrine therapy in selected patients), in-vitro fertilization protocols, and male contraception research. Recent practice has positioned triptorelin alongside leuprolide and goserelin as essentially equivalent options within the GnRH agonist class, with selection driven by formulation availability, depot interval preference, payer access, and clinician familiarity rather than meaningful efficacy differences.

How It Works

Triptorelin mimics the brain's natural GnRH hormone but is far more potent and long-lasting. When given continuously (via depot injection), it overwhelms the pituitary's GnRH receptors, causing them to shut down. This stops LH and FSH production, which in turn halts testosterone and estrogen production — effectively a reversible chemical castration useful for hormone-sensitive cancers and conditions.

Triptorelin (D-Trp6-GnRH) is a decapeptide superagonist with a D-tryptophan substitution at position 6 that increases binding affinity and metabolic stability. It is 13-fold more potent than native GnRH for LH release and 21-fold for FSH release. Acute administration triggers robust LH/FSH release via Gq/11-coupled GnRH receptor (GnRHR) signaling. Sustained exposure (depot formulations) causes receptor internalization, uncoupling from phospholipase C signaling, and transcriptional downregulation of GnRHR expression. The net result is castrate-level testosterone (<50 ng/dL) within 3-4 weeks. Depot formulations use biodegradable polymer microsphere technology (PLGA) for sustained release over 1, 3, or 6 months. Triptorelin pamoate and triptorelin acetate salt forms are used depending on formulation and release profile.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Triptorelin:

• 01Head-to-head triptorelin vs. leuprolide comparative outcomes — most class-level data treat the agents as interchangeable, but adequately powered head-to-head trials are limited; subtle differences in testosterone suppression onset, cardiovascular safety, and quality-of-life endpoints might exist.
• 02GnRH agonist vs. antagonist class selection in patients with cardiovascular comorbidity — the PRONOUNCE trial (degarelix vs. leuprolide) was inconclusive and similar dedicated triptorelin data is limited; optimal selection in high cardiovascular-risk patients remains debated.
• 03Single-dose 'PCT' use following anabolic-androgenic steroid administration — no controlled trials, no safety data, no efficacy data; this off-label use is widespread in bodybuilding contexts but lacks any evidence base.
• 04Optimal dose and duration of ovarian suppression in premenopausal breast cancer — international guidelines recommend triptorelin or goserelin in selected high-risk premenopausal women receiving tamoxifen or aromatase inhibitors, but optimal duration and patient-selection refinement is ongoing.
• 05Pediatric long-term outcomes after central precocious puberty treatment — long-term effects on adult height, bone density, fertility, and metabolic health following pediatric GnRH agonist treatment courses are being characterized in registry data.
• 06Combination with novel anti-androgens in biochemical recurrence — EMBARK established enzalutamide combinations; further sequencing and combination questions with apalutamide, darolutamide, and novel agents are evolving.

Forms & Administration

IM injection only. Trelstar: 3.75mg monthly depot, 11.25mg 3-month depot, or 22.5mg 6-month depot for prostate cancer. Triptodur: 22.5mg 6-month depot for central precocious puberty. Decapeptyl (international): 3.75mg monthly or 11.25mg 3-month depot for endometriosis and prostate cancer. All formulations use PLGA microsphere technology for sustained release. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Triptorelin is FDA-approved for advanced prostate cancer (Trelstar) and central precocious puberty (Triptodur). Endometriosis use is FDA off-label (though widely approved internationally as Decapeptyl). Off-label PCT use following anabolic steroid use has no clinical evidence base and is not supported. Triptorelin should be prescribed by a clinician familiar with the relevant indication.

Timeline of Effects

Common Questions

Who Triptorelin Is NOT For

Drug & Supplement Interactions

Triptorelin's drug-interaction profile largely mirrors leuprolide's. Peptide proteolytic clearance does not engage CYP-mediated metabolism, so classical pharmacokinetic interactions are minimal. The clinically important interactions are pharmacodynamic. Anti-androgens (bicalutamide, flutamide, nilutamide, enzalutamide): co-administration is standard practice during the testosterone flare period and as continued combined androgen blockade. Recent trial data (EMBARK with enzalutamide, EMBARK post-hoc analyses with triptorelin where applicable) define expanded combined-blockade indications. QT-prolonging medications: triptorelin can prolong QT interval, and combination with other QT-prolonging agents warrants ECG monitoring and electrolyte management. Diabetic medications: long-term ADT alters insulin sensitivity and increases diabetes risk; medication adjustments may be needed. Antihypertensives and cardiac medications: ADT affects lipid profiles and cardiovascular physiology over time; medication adjustments may be needed. Warfarin: minimal documented direct interaction, but overall metabolic shifts during ADT can affect anticoagulation control; INR monitoring should continue with attention during initiation. Corticosteroids: commonly used together in prostate cancer for symptom management; the combination is intended. Hyperprolactinemia-associated drugs (some antipsychotics, metoclopramide, certain antidepressants): can theoretically interact with HPG-axis dynamics, though clinical significance during established triptorelin suppression is modest. As with any chronic specialty therapy, patients should disclose all prescription, OTC, and supplement use to their prescriber.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions